Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Slavomir Krajnak"'
Autor:
Ina Shehaj, Slavomir Krajnak, Katrin Almstedt, Yaman Degirmenci, Sophia Herzog, Antje Lebrecht, Valerie Catherine Linz, Roxana Schwab, Kathrin Stewen, Walburgis Brenner, Annette Hasenburg, Marcus Schmidt, Anne-Sophie Heimes
Publikováno v:
Biomedicines, Vol 12, Iss 6, p 1361 (2024)
Breast cancer (BC) poses a challenge in establishing new treatment strategies and identifying new prognostic and predictive markers due to the extensive genetic heterogeneity of BC. Very few studies have investigated the impact of mRNA expression of
Externí odkaz:
https://doaj.org/article/436bd216dafe4472bd66a3ed096dbda2
Autor:
Ina Shehaj, Maria Schröder, Valerie Catherine Linz, Slavomir Krajnak, Katrin Almstedt, Kathrin Stewen, Roxana Schwab, Annette Hasenburg, Marcus Schmidt, Anne-Sophie Heimes
Publikováno v:
Cancers, Vol 16, Iss 7, p 1371 (2024)
Background: Immune checkpoint inhibitors (ICIs) have emerged as an essential therapeutic approach in treating many solid tumors. ICIs enhance the body’s anti-tumor T-cell activity, resulting in a novel spectrum of immunotherapy-related side effects
Externí odkaz:
https://doaj.org/article/51ede6d68ed447f9a04882c1f773442d
Autor:
Slavomir Krajnak, Jannis Patrik Trier, Pauline Friederike Heinzmann, Katharina Anic, Anne-Sophie Heimes, Amelie Loewe, Marcus Schmidt, Marco Johannes Battista, Annette Hasenburg, Walburgis Brenner
Publikováno v:
EXCLI Journal : Experimental and Clinical Sciences, Vol 22, Pp 114-130 (2023)
In metastatic breast cancer (MBC), PIK3CA mutations, activating the phosphatidylinositol 3-kinase (PI3K) signaling pathway seem to be associated with chemotherapy resistance and poor outcome. Inhibition of the PI3K signaling pathway may lead to sensi
Externí odkaz:
https://doaj.org/article/f53593c33c4d41c089131f2ffb937c14
Autor:
Mona Wanda Schmidt, Walburgis Brenner, Susanne Gebhard, Marcus Schmidt, Susanne Singer, Lina Weidenbach, Harriett Hahn, Diana Puzankova, Bettina Blau-Schneider, Antje Lehnert, Marco Johannes Battista, Katrin Almstedt, Anja Lütkemeyer, Markus Philipp Radsak, Aline Mähringer-Kunz, Slavomir Krajnak, Valerie Cathrine Linz, Roxana Schwab, Boris Gabriel, Annette Hasenburg, Katharina Anic
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Fatigue is a very common side effect during intravenous chemotherapy. Unfortunately, only few effective therapeutic options are available, mostly based on daily activity. In our pilot trial we were able to demonstrate that intermittent fasting can re
Externí odkaz:
https://doaj.org/article/6474b128f3b1416b8f4dbe20fd706650
Autor:
Anne-Sophie Heimes, Natali Riedel, Katrin Almstedt, Slavomir Krajnak, Roxana Schwab, Kathrin Stewen, Antje Lebrecht, Marco Johannes Battista, Walburgis Brenner, Annette Hasenburg, Marcus Schmidt
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 20, p 15219 (2023)
Due to a higher mutational load, triple-negative breast cancer (TNBC) is characterized by a higher immunogenicity compared to other subtypes. In this context, we analyzed the prognostic significance of tumor-infiltrating plasma cells in a cohort of 1
Externí odkaz:
https://doaj.org/article/a6f440fbcf06470bbc5e1e98fdcecde8
Autor:
Wojciech A. Cieślikowski, Tobias Haber, Slavomir Krajnak, Katharina Anic, Annette Hasenburg, Rene Mager, Joachim W. Thüroff, Walburgis Brenner
Publikováno v:
EXCLI Journal : Experimental and Clinical Sciences, Vol 20, Pp 1585-1596 (2021)
After prostatectomy due to prostate carcinoma, patients often develop metastases. Although prostate cancer is susceptible to hormonal manipulation, many patients become castration-resistant. Therefore, new therapies are the focus of investigations. W
Externí odkaz:
https://doaj.org/article/5142eb0711f942aeae9d5e702906020c
Autor:
Katharina Anic, Mona Wanda Schmidt, Marcus Schmidt, Slavomir Krajnak, Amelie Löwe, Valerie Catherine Linz, Roxana Schwab, Wolfgang Weikel, Walburgis Brenner, Christiane Westphalen, René Rissel, Erik Kristoffer Hartmann, Roland Conradi, Annette Hasenburg, Marco Johannes Battista
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionPerioperative red blood cell (RBC) transfusions have been associated with increased morbidity and worse oncological outcome in some solid neoplasms. In order to elucidate whether RBC transfusions themselves, the preoperative anemia of can
Externí odkaz:
https://doaj.org/article/65e41404297f4447affa667ecd2b7f2d
Autor:
Roxana Schwab, Kathrin Stewen, Theresa-Louise Bührer, Mona W. Schmidt, Josche van der Ven, Katharina Anic, Valerie C. Linz, Bashar Haj Hamoud, Walburgis Brenner, Katharina Peters, Anne-Sophie Heimes, Katrin Almstedt, Slavomir Krajnak, Wolfgang Weikel, Marco J. Battista, Christian Dannecker, Annette Hasenburg
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 5, p 2048 (2023)
Background: Lymph node involvement is the most important prognostic factor for recurrence and survival in vulvar cancer. Sentinel node (SN) procedure can be offered in well-selected patients with early vulvar cancer. This study aimed to assess curren
Externí odkaz:
https://doaj.org/article/40df9919ee8248408f7b4f2e0d5c5c81
Autor:
Katrin Almstedt, Lisa Krauthauser, Franziska Kappenberg, Daniel-Christoph Wagner, Anne-Sophie Heimes, Marco J. Battista, Katharina Anic, Slavomir Krajnak, Antje Lebrecht, Roxana Schwab, Walburgis Brenner, Wolfgang Weikel, Jörg Rahnenführer, Jan G. Hengstler, Wilfried Roth, Annette Hasenburg, Kathrin Stewen, Marcus Schmidt
Publikováno v:
Cancers, Vol 15, Iss 5, p 1413 (2023)
We examined differences in HER2 expression between primary tumors and distant metastases, particularly within the HER2-negative primary breast cancer cohort (HER2-low and HER2-zero). The retrospective study included 191 consecutive paired samples of
Externí odkaz:
https://doaj.org/article/e2d9297432b0494988a0cdae22143027
Autor:
Anne-Sophie Heimes, Katrin Almstedt, Slavomir Krajnak, Anne Runkel, Annika Droste, Roxana Schwab, Kathrin Stewen, Antje Lebrecht, Marco J. Battista, Walburgis Brenner, Annette Hasenburg, Mathias Gehrmann, Jan G. Hengstler, Marcus Schmidt
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2656 (2022)
Background: Monoclonal antibodies against PD-1 or PD-L1 have been established in clinical practice for the treatment of both early and advanced/metastatic triple-negative breast cancer. Beyond the established immune checkpoints (ICPs) (PD-1 and CTLA-
Externí odkaz:
https://doaj.org/article/34dbf5ecf98d4a23af271fabb54d11b1